HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cosmetics Director: ‘Sporadic’ WEN AERs Make Case For Mandatory Reporting

This article was originally published in The Rose Sheet

Executive Summary

In a Q&A posting, FDA Office of Cosmetics and Colors Director Linda Katz offered perspective on how the division handles adverse event reports and makes a case for mandatory AE reporting. She also explains how FDA reacted when WEN-related AERs began rolling in.

You may also be interested in...



Cosmetics Recalls For August-October Period Have One Familiar Thing In Common: All Were Voluntary

Under current cosmetics regulations FDA does not have the authority to order product recalls, as it does in the dietary supplement space, for example. Voluntary cosmetic recalls have been typically light in recent months, most often citing microbiological issues.

FDA To Curtail Cosmetics Safety Work Under FY 2018 Budget Constraints

President Trump's budget proposal for fiscal 2018 calls for "targeted reductions to the Food Safety program, including reducing staff levels through attrition." In its justification to congressional appropriators, FDA says it will reduce funding for cosmetics safety work in order to focus on top priorities in the broad foods area.

FDA Research Seeks Better Understanding Of Talc’s Potential Cancer Link

FDA’s Office of Cosmetics and Colors is heading up laboratory studies to explore an issue central to rampant litigation – talc’s effects on female genital system tissues, supported by a grant from the agency’s Office of Women’s Health. The agency is still finalizing a scientific literature review, but expects its research will help fill gaps that have not been adequately covered by epidemiologic and animal studies to date.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS108737

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel